ASND News and Press, Ascendis Pharma A/S

2026-02-27 22:31:48 ET More on Ascendis Pharma Ascendis Pharma FY 2025 Results: More Than A Takeover Story Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript Ascendis: Why I'm Skeptical On Takeover Rumors, Long-Term Targets Ascendis Pharma Q4 2025 Ea...

The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing interval Commercial availability expected during early part of Q2 2026 Rare Pediatric Disease Priority Review Voucher granted in connection with approval Ascendis to...

2026-02-23 14:26:14 ET Image source: The Motley Fool. Wednesday, February 11, 2026 at 4:30 p.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-12 07:33:45 ET Thesis Over the past couple of month we've seen Ascendis Pharma ( ASND ) shares move higher due to some speculative takeover news. Back in January, shares saw a 7.5% jump after traders again circulated fresh takeover chatter tied to a Betaville uncooked al...

2026-02-11 20:24:19 ET Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call February 11, 2026 4:30 PM EST Company Participants Chad Fugure - Vice President of Investor Relations Jan Mikkelsen - President, CEO, Member of Executive Board & Executive Director Scott Sm...

2026-02-11 19:50:19 ET Image source: The Motley Fool. Wednesday, February 11, 2026 at 4:30 p.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-11 16:04:55 ET More on Ascendis Pharma Ascendis: Why I'm Skeptical On Takeover Rumors, Long-Term Targets Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Resul...

Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 million Q4 2025 operating profit of €10 million and cash flow from operating activities of €73 million TransCon ® CNP under FDA Priority Review, PDUFA action goal date of Februa...

Sun Life Financial Inc. (SLF) is expected to report $1.35 for Q4 2025 Copa Holdings S.A. Class A (CPA) is expected to report $4.4 for Q4 2025 Nabors Industries Ltd. (NBR) is expected to report $-2.93 for Q4 2025 Intercorp Financial Services Inc. (IFS) is expected to report $1.1 for Q4...

2026-02-10 17:35:51 ET More on Ascendis Pharma Ascendis: Why I'm Skeptical On Takeover Rumors, Long-Term Targets Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Resul...